Recombinant Vaccines for Prevention of AIDS and Other Diseases

用于预防艾滋病和其他疾病的重组疫苗

• 批准号: 10014024
• 负责人: Bernard Moss
• 金额: $ 77.3万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10014024
• 关键词: Acquired Immunodeficiency Syndrome; Animals; Antigens; Cellular Immunity; DNA Vaccines; Disease; HIV Envelope Protein gp120; HIV vaccine; Immunization; Laboratories; Phase I Clinical Trials; Phase II Clinical Trials; Poxviridae; Prevention; Proteins; Recombinant Proteins; Recombinant Vaccines; Research; Testing; Vaccines; Viral; Viral Antigens; Viral Vector; Virus-like particle; immunogenic; improved; nonhuman primate; recombinant virus vaccine; side effect; vaccine candidate; vaccinia virus vector; vector; vector vaccine

There are many diseases for which there are no vaccines and others for which the vaccines are not optimal or have significant side effects. The objectives of this project are to develop new vectors, characterize viral antigens, determine targets of humoral and cell mediated immunity, and use this information to develop candidate vaccines. Live recombinant viral vaccines, DNA vaccines and recombinant protein vaccines are being developed. Presently we are working on vaccinia virus-vectored vaccines for HIV. The vaccines are first tested in small animals and then in non-human primates. Phase 1 and 2 clinical trials with MVA-vectored vaccines developed in our laboratory are ongoing by collaborators. The vaccines were safe and immunogenic. Animal studies revealed good boosting of MVA primed immunizations with gp140 and trimeric gp120 proteins and with virus-like particles.

有许多疾病是没有疫苗的，而其他一些疾病的疫苗并不是最理想的或有显著的副作用。该项目的目标是开发新的载体，表征病毒抗原，确定体液免疫和细胞免疫的靶标，并利用这些信息开发候选疫苗。正在开发重组病毒活疫苗、DNA疫苗和重组蛋白疫苗。目前，我们正在研制针对HIV的痘苗病毒载体疫苗。这些疫苗首先在小动物身上进行测试，然后在非人类灵长类动物身上进行测试。我们实验室开发的MVA载体疫苗的第一阶段和第二阶段临床试验正在由合作者进行。疫苗是安全的和免疫原性的。动物研究表明，使用gp140和三聚体gp120蛋白以及病毒样颗粒可以很好地增强MVA启动的免疫。